C W Wallwiener1,2, A D Hartkopf3, E Grabe3, M Wallwiener4, F-A Taran3, T Fehm5, S Y Brucker6, B Krämer3. 1. Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstraße 7, 72076, Tübingen, Germany. cwallwiener@gmail.com. 2. Department of Women's Health, University of Tuebingen, Calwerstrasse 7, 72076, Tübingen, Germany. cwallwiener@gmail.com. 3. Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstraße 7, 72076, Tübingen, Germany. 4. Department of Obstetrics and Gynecology, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany. 5. Department of Obstetrics and Gynecology, University of Duesseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany. 6. Department of Women's Health, University of Tuebingen, Calwerstrasse 7, 72076, Tübingen, Germany.
Abstract
PURPOSE: To establish whether women over 65 years of age with newly diagnosed with breast cancer (BC) receive adjuvant chemotherapy less frequently than younger postmenopausal women and whether comorbidity influences this potential undertreatment. MATERIALS AND METHODS: In a single-site, retrospective, comparative study, postmenopausal early stage BC patients treated between 01/2001 and 12/2005 at a major German university hospital were analyzed in two age Groups A and B (≥65 vs. <65 years) for initiation and completion of guideline-recommended adjuvant chemotherapy. Risk stratification was based on the 2005 St. Gallen Consensus Conference criteria. Comorbidity was parametrized using the Charlson Comorbidity Index (CCI). RESULTS: Analysis included 634 patients, 380 in Group A and 254 in Group B. Mean age (range) was 73 (65-94) and 61 (55-64) years, respectively. The proportion of patients from Group A given ≥3 cycles of chemotherapy was significantly decreased as compared to Group B. 52 % of patients with CCI <3 but only 20 % with CCI ≥3 were recommended to undergo chemotherapy (p < 0.001). Median follow-up [95 % confidence interval (CI)] was 85 (82-88) months. DFS was significantly shorter in patients aged ≥65 years as compared to younger postmenopausal patients (HR, 0.598; 95 % CI, 0.358-0.963; p = 0.048). CONCLUSIONS: Despite being high-risk patients, older women with early stage BC were often not given guideline-recommended chemotherapy. Higher recurrence rates compared with younger postmenopausal women suggest that older patients are undertreated. Treatment needs to be adapted to general health and tumor biology rather than age. More trials in elderly BC patients are needed.
PURPOSE: To establish whether women over 65 years of age with newly diagnosed with breast cancer (BC) receive adjuvant chemotherapy less frequently than younger postmenopausal women and whether comorbidity influences this potential undertreatment. MATERIALS AND METHODS: In a single-site, retrospective, comparative study, postmenopausal early stage BC patients treated between 01/2001 and 12/2005 at a major German university hospital were analyzed in two age Groups A and B (≥65 vs. <65 years) for initiation and completion of guideline-recommended adjuvant chemotherapy. Risk stratification was based on the 2005 St. Gallen Consensus Conference criteria. Comorbidity was parametrized using the Charlson Comorbidity Index (CCI). RESULTS: Analysis included 634 patients, 380 in Group A and 254 in Group B. Mean age (range) was 73 (65-94) and 61 (55-64) years, respectively. The proportion of patients from Group A given ≥3 cycles of chemotherapy was significantly decreased as compared to Group B. 52 % of patients with CCI <3 but only 20 % with CCI ≥3 were recommended to undergo chemotherapy (p < 0.001). Median follow-up [95 % confidence interval (CI)] was 85 (82-88) months. DFS was significantly shorter in patients aged ≥65 years as compared to younger postmenopausal patients (HR, 0.598; 95 % CI, 0.358-0.963; p = 0.048). CONCLUSIONS: Despite being high-risk patients, older women with early stage BC were often not given guideline-recommended chemotherapy. Higher recurrence rates compared with younger postmenopausal women suggest that older patients are undertreated. Treatment needs to be adapted to general health and tumor biology rather than age. More trials in elderly BC patients are needed.
Entities:
Keywords:
Age; Breast cancer; Elderly; Postmenopausal women; Survival; Treatment response
Authors: Elke Peters; Tobias Anzeneder; Christian Jackisch; Thomas Dimpfl; Georg Kunz; Alexander Katalinic; Annika Waldmann Journal: Dtsch Arztebl Int Date: 2015-08-31 Impact factor: 5.594
Authors: Mara A Schonberg; Edward R Marcantonio; Donglin Li; Rebecca A Silliman; Long Ngo; Ellen P McCarthy Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Alice B Kornblith; Lan Lan; Laura Archer; Ann Partridge; Gretchen Kimmick; Clifford Hudis; Eric Winer; Rebecca Casey; Samantha Bennett; Harvey Jay Cohen; Hyman B Muss Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 44.544
Authors: Stacy Woodard; Padma C Nadella; Linda Kotur; John Wilson; William E Burak; Charles L Shapiro Journal: Cancer Date: 2003-09-15 Impact factor: 6.860
Authors: R Van Ewijk; A Wöckel; T Gundelach; K Hancke; W Janni; S Singer; R Kreienberg; M Blettner; L Schwentner Journal: Arch Gynecol Obstet Date: 2014-09-02 Impact factor: 2.344
Authors: Clark Dumontier; Kerri M Clough-Gorr; Rebecca A Silliman; Andreas E Stuck; André Moser Journal: J Geriatr Oncol Date: 2016-12-13 Impact factor: 3.599
Authors: María Vallet-Regí; Miguel Manzano; Leocadio Rodriguez-Mañas; Marta Checa López; Matti Aapro; Lodovico Balducci Journal: Oncologist Date: 2017-02-20
Authors: Gabrielle B Rocque; Nicole E Caston; Jeffrey A Franks; Courtney P Williams; Monica S Aswani; Andres Azuero; Risha Gidwani Journal: Breast Cancer Res Treat Date: 2021-09-29 Impact factor: 4.872
Authors: Clark DuMontier; Kah Poh Loh; Paul A Bain; Rebecca A Silliman; Tammy Hshieh; Gregory A Abel; Benjamin Djulbegovic; Jane A Driver; William Dale Journal: J Clin Oncol Date: 2020-04-06 Impact factor: 50.717
Authors: E C Inwald; O Ortmann; M Koller; F Zeman; F Hofstädter; M Evert; G Brockhoff; M Klinkhammer-Schalke Journal: Breast Cancer Res Treat Date: 2017-02-15 Impact factor: 4.872
Authors: Sophia Scharl; Tim Sprötge; Michael Gerken; Anton Scharl; Atanas Ignatov; Elisabeth C Inwald; Olaf Ortmann; Oliver Kölbl; Monika Klinkhammer-Schalke; Thomas Papathemelis Journal: Arch Gynecol Obstet Date: 2021-07-05 Impact factor: 2.344